Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:19:14 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Z:NVS - NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) - https://www.novartis.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NVS - Z0.8156.22·170.420.1156.42+2.5751.73,012.0464,87722,638154.03  156.615  153.90154.95  97.71519:58:11Sep 3015 min RT 2¢

Recent Trades - Last 10 of 22638
Time ETExPriceChangeVolume
19:58:11Z156.252.301
19:11:10Z156.722.7730
18:22:07Z155.721.7713
17:50:41Z156.953.001
17:36:24Z156.993.044
17:24:16Z156.993.0499
17:01:39Z156.402.4550
16:59:16Z155.441.498
16:59:16Z155.401.455
16:59:16Z155.401.451

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-09-30 17:23U:NVSNews ReleaseNovartis receives FDA approval for Rhapsido(TM) (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
2025-09-03 07:00U:NVSNews ReleaseArgo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
2025-08-11 01:20U:NVSNews ReleaseNovartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjogren's disease
2025-07-31 16:30U:NVSNews ReleaseNovartis twice-yearly* Leqvio(TM) (inclisiran) receives FDA approval for new indication enabling first-line use
2025-07-03 01:25U:NVSNews ReleaseNovartis provides update on Phase III GCAptAIN study of Cosentyx(TM) in giant cell arteritis (GCA)
2025-06-20 08:55U:NVSNews ReleaseNYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth
2025-04-02 20:29U:NVSNews ReleaseNovartis receives FDA accelerated approval for Vanrafia(TM) (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
2025-03-20 19:37U:NVSNews ReleaseNovartis receives third FDA approval for oral Fabhalta(TM) (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
2025-02-28 09:00U:NVSNews ReleaseNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)